Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (16910)	1/15/2004 9:10:43 AM
From: rrufff	Respond to of 120415

BSDM-Press Release Source: BSD Medical Corp. Prime Time Television Introduces BSD Medical's Technology in New Super-Therapy for Cancer Thursday January 15, 8:06 am ET SALT LAKE CITY, Jan. 15 /PRNewswire-FirstCall/ -- BSD Medical Corp. (OTC Bulletin Board: BSDM - News) today announced that its advanced cancer treatment systems have been introduced on prime-time German state television as a key component for a new tri-modality super-therapy for cancer. By using a combined tri-modality punch (radiation + chemotherapy + hyperthermia, provided by BSD Medical), the biweekly medical series, "The Consulting Hour," explained last Monday evening how previously inoperable cancer can often be shrunk, brought into control and then removed through conservative surgery. This objective is not only improved survival, but also sparing patients from the devastating effects of radical surgery, such as loss of the bladder or other organs, and amputation of limbs. The broadcast first showed a patient with advanced bladder cancer being treated in a BSD-2000/3D hyperthermia system at Erlangen University Medical School. This patient was receiving treatment under an innovative protocol (the tri-modality treatment) designed to avoid radical bladder surgery. Professor Rolf Sauer, who serves as the Medical Director, explained that about 25% of bladder cancer patients relapse, "and for those patients we have adopted our innovative treatment protocol with adjuvant deep regional hyperthermia." The program also featured a BSD-2000/3D/MR hyperthermia system located at LMU Munich University Medical School. This integrated hyperthermia and MR system developed in collaboration between BSD Medical and Siemens Medical allows physicians to see temperature changes and the progress of the treatment using magnetic resonance images (MRI). The primary use of this system is to treat first and second line tumors using the new tri-modality therapy. The objective is again to shrink otherwise inoperable tumors, allowing them to be removed through conservative surgery. Prof. Rolf Issels, who is chairman of the department and head of the Clinical Cooperative Group for Hyperthermia, said, "Here we use our tri-modal chemoradiotherapy with adjuvant deep regional hyperthermia as a first line therapy following an approved EORTC protocol for the treatment of soft tissue sarcomas, with the purpose of avoiding amputations, improving local control and increasing long-term survival." Prof. Issels further pointed out the role of heat shock proteins in hyperthermia treatment. Hyperthermia triggers the creation of heat shock proteins, stimulating the patient's "sleeping" immune system, causing it to awake, recognize and attack the tumor with killer cells. American medicine is also focusing on the benefits of this tri-modality super-therapy through research being funded by the National Institutes of Health. The July 15, 2003 issue of CANCER devoted both an article and an editorial article to the new tri-modality therapy (radiation + chemotherapy + hyperthermia). The editorial is entitled, "Hyperthermia and Its Modern Use in Cancer Treatment." Along with its demonstrated ability to kill cancer cells directly, hyperthermia has long been shone to boost the effectiveness of both radiation and chemotherapy. The concept of the triple therapy is therefore to attack cancer by using hyperthermia to create "super-radiation" and "super- chemotherapy," aided by direct cancer cell kill from hyperthermia itself. BSD Medical produces sophisticated microwave systems used to precisely elevate the temperature of cancerous tumors, directly killing cancerous cells and significantly enhancing the effectiveness of certain other cancer therapies, including radiation and chemotherapy. To learn more about BSD Medical and hyperthermia therapy, visit www.bsdmc.com . Statements contained in this press release that are not historical facts are forward looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's filings with the Securities and Exchange Commission) that could cause actual results to differ materially from estimated results.